HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
Số trang: 10
Loại file: pdf
Dung lượng: 1.05 MB
Lượt xem: 8
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
HER2 expression has a prognostic and predictive impact in early-stage breast cancer (BC). HER2 positive BC (immunohistochemistry (IHC) score 3+or 2+with in situ hybridization (ISH) amplifcation) are treated with HER2 targeted therapies.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Antibody–drug conjugates HER2-low Breast cancer Trastuzumab–deruxtecan Neoadjuvant treatmentGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 167 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 139 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 109 0 0 -
12 trang 87 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 35 0 0
-
11 trang 35 0 0
-
12 trang 33 0 0